Rockefeller Capital Management L.P. Cuts Stock Position in Kenvue Inc. $KVUE

Rockefeller Capital Management L.P. cut its position in Kenvue Inc. (NYSE:KVUE) by 76.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 148,932 shares of the company’s stock after selling 486,217 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Kenvue were worth $2,569,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Elyxium Wealth LLC bought a new position in shares of Kenvue during the 4th quarter worth approximately $26,000. Physician Wealth Advisors Inc. grew its holdings in Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares during the last quarter. MV Capital Management Inc. purchased a new position in Kenvue in the fourth quarter worth $28,000. Reflection Asset Management acquired a new position in shares of Kenvue during the fourth quarter worth $32,000. Finally, SBI Securities Co. Ltd. increased its position in shares of Kenvue by 82.4% during the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after purchasing an additional 1,027 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Performance

Shares of KVUE stock opened at $19.09 on Tuesday. The business has a fifty day moving average of $17.70 and a 200 day moving average of $17.65. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $22.87. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. The firm has a market capitalization of $36.66 billion, a price-to-earnings ratio of 22.46, a price-to-earnings-growth ratio of 1.45 and a beta of 0.54.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. During the same quarter in the previous year, the business earned $0.24 EPS. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. As a group, research analysts expect that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were issued a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.3%. The ex-dividend date was Wednesday, May 13th. Kenvue’s dividend payout ratio is 97.65%.

Insider Transactions at Kenvue

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.59% of the company’s stock.

Analysts Set New Price Targets

KVUE has been the subject of a number of recent analyst reports. Argus raised Kenvue to a “hold” rating in a research report on Friday, March 6th. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. UBS Group decreased their price target on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Citigroup lowered their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, April 15th. Finally, Barclays cut their price objective on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 14th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and twelve have issued a Hold rating to the company’s stock. According to data from MarketBeat, Kenvue currently has a consensus rating of “Hold” and a consensus target price of $19.33.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.